Introduction
Platelets are small, anucleate blood cells of 2-3 lm in diameter that are released from multinucleate megakaryocytes (MKs) in the bone marrow. Platelets are indispensable for hemostasis and defects in platelet production and/ or function leads to a variety of bleeding complications. Incompetency in production due to hematological diseases or treatment modalities such as cancer chemotherapy, radiotherapy, or hematopoietic stem cell transplantation conditioning can lead to thrombocytopenia. Massive loss or consumption due to trauma, cardiac surgery, severe infection, or hypercoagulation syndromes could also lead to thrombocytopenia [1] .
As a clinical measure to compensate for the reduced number of platelets in these patients, the allotransfusion of platelets has been standard therapy for many decades [2, 3] . Platelet transfusion products are provided through blood donation systems and have saved numerous lives. While this well-established system has satisfactorily managed major issues in terms of supply and safety, there are still several limitations to be considered. Platelet products are stored at room temperature with gentle agitation to best maintain their viability, but they also have a shelf life of only up to 5 days based on their hemostatic capacity and the risk of bacterial flourish. Therefore, the constant restocking of platelet products is required. However, blood donors are unreliable due to capricious schedules caused by bad weather, holidays, etc., which can lead to the shortage or wasted excess of platelet products [4] . Moreover, an absolute shortage of supply is anticipated in developed nations with aging societies [5, 6] .
The nature of allotransfusion inevitably accompanies the risk of blood-borne infections and alloimmunityrelated complications [3] . Products contaminated with infective agents such as hepatitis viruses, HIV, HTLV, or other viruses are effectively screened out using highly sensitive methods such as PCR, but still cannot be completely eliminated because of the window period for their detection. Platelets preserved at room temperature are also vulnerable to bacterial contamination. Moreover, unlike alloimmune responses such as transfusion-associated graft-versus-host disease (GVHD), which is preventable by the depletion of leukocytes or the irradiation of blood products, platelet transfusion refractoriness (PTR) caused by allograft rejection due to human leukocyte antigen (HLA) or human platelet antigen (HPA) mismatches has not been resolved [7] . Furthermore, cytokines and other bioactive substances included in the serum of platelet products are also thought to contribute to complications such as fever, allergic symptoms, and transfusion-related acute lung injury (TRALI).
Producing platelets ex vivo from induced pluripotent stem cells (iPSCs) can potentially resolve the issues that come with allotransfusion products. From the point of view of regenerative medicine, the safety concerns of iPSC-derived platelets, such as tumorigenesis, are minimal, but the number of cells required is several orders of magnitude higher when compared with other cellular therapies. Bearing such expectation and challenge, many key advances have been made in the production of iPSCderived platelets such that their clinical application could be realized within a few years. In this review, we aim to summarize state-of-the-art development in the ex vivo production of iPSC-derived platelets with remarks on expandable MK lines, bioreactor systems, and newly discovered reagents. As an important potential development, procedures made possible using iPSC-derived platelets to overcome alloimmune-related complications will also be mentioned.
iPSCs as the starting cell source
The ex vivo production of platelets is independent of blood donors and can potentially bring a stable and safe supply of platelet products. Platelets can be prepared from a certified pathogen-free cell source manufactured in contamination-free conditions with relatively little concern of donor availability. Rather, the primary challenge is platelet quantity. In typical therapy, a large number of platelets, that is, 200 or 300 billion, are administered as a single transfusion dose. Because platelets are non-proliferating anucleate cells that can circulate for only 3-10 days, transfusion is required repeatedly unless the patient's platelet production recovers. As a first step toward sufficient ex vivo platelet yield, the production of a source that can be robustly expanded ex vivo was developed.
MKs are the unipotent progenitors of platelets, but reside in bone marrow as a very minor population, making them impractical as a cell source. The upstream multipotent progenitor of MKs, hematopoietic stem cells (HSCs), can be obtained with no invasive procedure from umbilical cord blood (UCB). However, one unit of UCB contains only around 1 million HSCs [8] , meaning highly efficient expansion, differentiation, and platelet release are required [9] . Unfortunately, the expansion of HSCs ex vivo for MK production has not reached satisfactory level, making this option also impractical (Table 1) .
Further upstream populations, namely pluripotent stem cells (PSCs), which include embryonic stem cells (ESCs) and iPSCs, have gained attention [10, 11] . Unlike HSCs, PSCs can be expanded indefinitely in vitro and differentiate to MKs and eventually platelets [12] [13] [14] [15] [16] [17] . Intriguingly, HSCs have not been detected in this differentiation process, despite them being considered a mandatory intermediate for PSCs to take MK lineage. The reason for their absence is not well understood. Nevertheless, platelets produced in this way behave similar to circulating human blood platelets.
While human ESCs can be obtained only from earlystage embryos, functionally equivalent human iPSCs can be generated from somatic cells upon the introduction of a set of defined reprogramming genes, meaning iPSCs can be obtained with less invasiveness and ethical arguments [10, 11] . However, studies that expand iPSCs to a sufficient level and then differentiate them to platelets have not reached clinical trials, likely due to the long, complex, and costly process and the low efficiency in their differentiation to MKs, which results in infeasible scale of cultivation and significant variance among batches (Table 1) . Nevertheless, the ease of genetic manipulation in iPSCs has enabled the overexpression of specific sets of genes to establish expandable MK lines, the cell source currently considered most suitable as master cells for producing platelets [18, 19] . Meanwhile, unlike HSCs or ESCs, even if only a small amount of skin specimen, peripheral blood, cord blood, or urine [20] is obtained, iPSCs can be generated from basically any donor, even those with hematological disorders. Therefore, autologous iPSCs and iPSCs from HLA-homologous-type donors currently stocked in a library as sources for allografts are possible (Table 1 ) [21] [22] [23] . Furthermore, by manipulation of the HLA or HPA expression, iPSC-derived platelets could evade alloimmune responses elicited by these molecules [17, 24, 25] .
Megakaryopoiesis and expandable MK lines
MKs and erythroblasts have been postulated to differentiate from a common progenitor, MK-erythroid progenitors (MEPs), in their ontogeny [26] . In this mechanism, thrombopoietin (TPO) and its receptor, c-MPL, play primary roles in the expansion, differentiation, and maturation of MKs [27] . Indeed, TPO, in combination with other cytokines and soluble factors, differentiates MKs in vitro [17, [28] [29] [30] .
Recently, in adult hematopoiesis, a progenitor committed specifically to MK lineage, MkPs, has been suggested to rise directly from HSCs or multipotent blood progenitors [31] , and the existence of MKs with selfrenewing capacity has been indicated [32, 33] (Fig. 1) . To obtain self-renewing MkPs, Nakamura et al. established immortalized MK progenitor cell lines (imMKCLs) by the sequential introduction of c-MYC and BMI1 genes followed by the BCL-XL gene into human iPSC-derived hematopoietic progenitor cells cultivated in MK-differentiating condition ( Table 2 ). These transgenes were under the control of a Tet-on system, which allowed doxycycline (DOX) to switch imMKCLs from a self-renewing proliferation phase (DOX-on) to a platelet-producing maturation phase (DOX-off) [18] . The overexpression of c-MYC promotes the expansion of MKs without maturation [34, 35] , while the polycomb complex component BMI1 and anti-apoptotic factor BCL-XL suppress senescence and apoptosis via regulation of ARF and INK4A, and caspases, respectively [36] . The DOX-off state ceases the overexpression of these transgenes and increases the expression of GATA1 and NF-E2, which are crucial factors for MK maturation and differentiation [37, 38] .
As another approach to obtain expandable MK lines, Moreau et al. established forward programmed MKs (fopMKs) by overexpressing three transcription factors: GATA1, FLI1, and TAL1, which they selected from 101 candidate MK-specific genes ( Table 2 ). These three transcription factors were introduced into human iPSCs as part of a forward programming strategy to enhance MK commitment under feeder-free conditions. After an initial brief cultivation with fibroblast growth factor 2 (FGF2) and bone morphogenetic protein 4 (BMP4) to induce mesoderm differentiation, TPO and stem cell factor (SCF) were used for the derivation and maintenance of MKs, and then, TPO in combination with interleukin-1 beta (IL-1b) was used for the maturation to release platelets [19] .
Platelet production from expandable MKs needs less time and has higher efficiency than starting from iPSCs, [35] . Moreover, the MK lines can be cryopreserved and, upon demand, thawed and expanded for platelet production, making them suitable as master cells. Platelet products compatible with good manufacturing practice (GMP) guidelines can be manufactured using certified infectious agent-free MK master cells and sterile conditions (Fig. 2) . GMP is crucial for the clinical application of platelets products. One major concern about using iPSCs and genetically manipulated MKs is tumorigenicity. As discussed in section Purification, irradiation, and preservation of iPSC-derived platelets, proper purification and irradiation should mitigate this concern.
Alternatively, the derivation of MKs from adipose tissues has also been reported [39] . Furthermore, two groups directly converted fibroblasts into MK progenitors by genetically introducing three factors, NF-E2, MAFG, and MAFK, or six factors, GATA2, RUNX1, GATA1, TAL-1, LMO2, and c-MYC, (Table 2) [40, 41] . These transdifferentiation methods circumvent the use of hematopoietic progenitors or PSCs and thus could be more appropriate for quick obtainment of platelets.
Platelet biogenesis and bioreactor systems
The establishment of expandable MK lines is only one half of the problem; the MKs must then be maturated to release functional platelets at high efficiency. During maturation, MKs go through repeated endomitosis and become giant polypoid cells, reaching up to 100 lm diameter and have DNA content of up to 128N. Along with this increase in size, MKs expand and invaginate their cell membranes to form a demarcation membrane system (DMS). This process is accompanied by the budding of numerous proplatelets from the DMS into the sinusoidal vessels of the bone marrow. Proplatelets contain platelet organelles and exhibit platelet-sized swellings arranged in tandem that depend on the rearrangement of microtubules. At the very last stage of thrombopoiesis, anucleate particles are torn off from the tips of the proplatelet protrusions and enter the blood stream, where they are further fragmented to become smaller particle, that is, platelets. In this process, some platelets are derived partly through preplatelets [42] [43] [44] [45] . In contrast to this steady state mechanism of thrombopoiesis, which is tightly regulated by TPO, a new mechanism was found in response to severe infections or acute bleedings. Here, the inflammatory cytokine IL-1a induces MKs to quickly release platelets in a rupture-like fashion [46] (Fig. 3) . The platelets released in this fashion are larger and show minor impairment but intact thrombotic function. While the steady state mechanism is the primary model for platelet production ex vivo, this inflammatory-based mechanism may provide some insights on how to increase the efficiency of platelet derivation. In this regard, IL-1b, which shares the same receptors with IL-1a, has been used [19, 29, 47] .
One MK in the bone marrow is postulated to produce 1000 to 2000 platelets, but under in vitro static conditions, the rate is comparatively miniscule, at 3-10 platelets per cell [18, 48] . Furthermore, in vitro formed platelets are typically larger, have less responsiveness, and are less viable [18, 48, 49] . This huge gap has urged studies to seek conditions that enhance the maturation of MKs and quality of the platelet yield. For instance, chemotactic factors such as stromal-derived factor 1 (SDF-1), sphingosine 1-phosphate (S1P), and chemokine ligand 5 (CCL5, RANTES) were shown to enhance platelet production in mouse studies [50] [51] [52] . As for physical conditions, hypoxia, which exists within the bone marrow, could help expand MKs [53] , while hyperthermia could increase the MK differentiation [54] .
To further recapitulate physical conditions in vivo, various types of bioreactors have been designed (Table 3 ) [55] . Bioreactors incorporate three-dimensional culture, which increases the surface area of the MKs to promote proplatelet formation, and shear stress, which exists in the blood flow and induces platelet release from the tip of proplatelets within the bone marrow blood vessel in vivo [42, 56] . Interestingly, a similar process has been postulated in the lung as well [57, 58] . Bioreactors designed with optimal shear stress were found to significantly increase both the number and rate of platelets formed [59] . Coating scaffolds in the MK culture with fibronectin and TPO was also found to increase the generation of platelets [60] .
These findings have stimulated the development of systems that more efficiently produce platelets that are highly competent and not preactivated (Table 3 ). For example, Thon et al. designed a chip-based bioreactor that recapitulates the chemical and physical components of bone marrow such as stiffness, extracellular matrix composition, pore size, endothelial cell contacts, and optimal shear stress flow [61] . Additionally, their bioreactor was able to incorporate live-cell microscopy. Our group suggested that the angle of flow may be an important parameter, as different angles were found to correlate with different platelet outputs, with 60 o being optimal [48] . In an attempt to recapitulate the bone marrow niche environment for MKs, Balduini and colleagues utilized a unique artificial scaffold made from silk protein harboring cytokines, extracellular matrix components, and endothelial-derived proteins [47, 62] . Blin et al. built a microfluidic device that captures MKs in VWF-coated micropillars and releases platelets depending on controlled shear rates [63] . Using a nanofiber membranebased bioreactor with shear flow, Avanzi et al. assembled a stepwise platelet-production line from cord blood cellderived CD34 + cells [64] . However, considering the potential of MKs in vivo and the larger scale needed, bioreactors still have much room to increase the efficiency [55] .
An alternative approach for platelet production is to intravenously infuse live MKs into living beings by taking advantage of the lungs as a location of platelet synthesis [57, 58] . Here, the lung traps the MKs, which then release platelets into the pulmonary blood vessels, essentially converting the lungs into in vivo bioreactors [65, 66] .
Combining bioreactors with chemical substances that promote megakaryo-thrombopoiesis could further enhance platelet production. Candidate chemical substances include actin polymerization inhibitor and Rho kinase inhibitor, which enhance MK polyploidization and proplatelet formation [64, 67, 68] . Wnt3a and Wnt5a have been shown to induce MK proliferation and maturation [69] . Studies that found hypercholesterolemia promotes platelet production suggest that the optimal supplementation of cholesterol components in the culture medium may enhance platelet production from MKs [70, 71] . Interestingly, aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1) was found not only to enhance HSC expansion [72] [73] [74] , but also to increase the ploidy of MKs and enrich a platelet-production competent MK precursor in in vitro differentiation settings [73, 75] .
Purification, irradiation, and preservation of iPSC-derived platelets
The elimination of unwanted components and preservation of optimal function are no less important than efficient production. To package iPSC-derived platelets at donor-derived platelet concentrates, the produced platelets must be concentrated, purified, washed, and suspended in preserving solution. Purification and washing involve depleting nucleated cells and solutions used for the cultivation. Nucleated cells such as iPSCs are known to form teratoma upon transplantation in animals [11] . While iPSCs are unlikely to remain at the end of the platelet-production process, the product of MK line-derived platelets includes considerable amounts of MKs. Like iPSCs, expandable MKs are established through the introduction of transgenes including the oncogene c-MYC, and thus risk expansion while retaining immaturity [18, 19] , raising concerns that they too might develop tumors after infusion. In addition, the high concentration of nucleated cells forming cell aggregates may cause potentially lifethreatening clinical emergencies such as lung emboli. Separation of the nucleated cells can be performed using filters or centrifugation based on differences in size or specific gravity, respectively [48, 76, 77] . However, complete depletion of nucleated cells is difficult, as a thorough separation procedure would lower yield and significantly damage mechanically sensitive platelets. A benign solution to eliminate nucleated cells that remain after the separation process is exposure to irradiation, as performed in regular donor-derived blood products, to completely eliminate the chance of tumorigenesis. Because platelets are anucleate, they are resistant to DNA damage caused by irradiation. The property of iPSC-derived platelet products as non-tumorigenic is a huge advantage in terms of safety compared with other iPSC-related regenerative medicine products. Platelets are functionally optimal when preserved at room temperature, but for ex vivo production, cultivation at 37°C is required. This higher temperature activates metalloproteinases, a disintegrin and metalloproteinase domain 17 (ADAM17) and ADAM10. ADAM17 induces the ectodomain shedding of glycoprotein Iba (GPIba; CD42b), which is crucial for platelets to aggregate, while ADAM10 induces the shedding of GPVI, which is a collagen receptor that regulates platelet activation signaling. Metalloproteinase inhibitors, GM-6001 and MMP8-I, and the selective ADAM17 inhibitor, KP-457, retain the surface expression of GPIba and inhibit ADAM10 at high concentrations [78] [79] [80] . p38 MAPK inhibitors may also block GPIba shedding from na€ ıve platelets [81] , as oxidative stress induces p38 MAPK-dependent digestion of GPIba in human and mouse platelets [82] . However, this hypothesis is still debated, as one study showed p38 MAPK inhibitors do not have this effect on iPSC-derived platelets, but rather increased the number of iPSC-derived MKs [80] . Meanwhile, a new platelet storage buffer, BRS-A, which is based on clinically available bicarbonated Ringer's solution (BRS) and acid-citrate-dextrose formula A (ACD-A), maintains human platelets, including GPIba expression, for 7 days at room temperature [83] . A combination of these procedures to block the shedding of glycoproteins may significantly improve the quality of ex vivo produced platelets and contribute to a donor-independent iPSC-platelet supply system aimed at clinical use.
iPSC-derived platelets for immune complications
Immune complications observed in platelet transfusion include acute reactions such as fever, allergic reactions, and TRALI, and later reactions such as GVHD and PTR [3, 7, 84] . Cytokines, allergens, antibodies, and yet unknown bioactive substances have been attributed as their cause, and washed platelet products are effective to prevent acute reactions [3] . Accordingly, the washing of iPSC-derived platelets should similarly prevent acute reactions. As for transfusion-related GVHD, it is evoked by contaminating lymphocytes in the platelet concentrate and could be prevented by leukodepletion or irradiation [84] . In this regard, lymphocytes would not exist in iPSCderived platelet products as they cannot develop in MKdifferentiating conditions or from MK lines.
Immune PTR is based on alloimmunity. Platelets express alloantigens such as ABO, HLA class I, and HPA. Upon transfusion, alloimmune responses against these antigens result in rejection, or PTR, in 5-15% of patients [3, 7] . ABO major mismatch causes a shorter interval time before the next transfusion, but overall is a minor issue with no significant clinical outcome [85] . In contrast, HLA or HPA mismatch could lead to serious PTR, immediately requiring an effective measure to avoid serious bleeding complications [3, 7] .
Alloantibodies against incompatible HLA class I and to a lesser extent against HPA are the major cause of immune PTR and demonstrate a need for compatible platelet transfusion [7] . Some patients become sensitized and eventually produce antibodies to allo-HLA and HPA through pregnancies or previous platelet transfusions.
Currently, the transfusion of HLA-or HPA-compatible platelets is the sole available measure, but the supply is limited and requires extra cost and labor to call in compatible donors upon demand.
iPSC-derived platelets are capable of overcoming these issues by several approaches. One produces autologous platelets from patient-derived iPSCs, which should not elicit an alloimmune response. However, establishing autologous iPSCs, then making expandable MK lines, and finally producing platelets is a long and complex process with variable product quality.
An alternative approach is to prepare off-the-shelf prequalified allogeneic products that have less alloimmunogenic property. iPSCs from donors with homologous-type class I HLA have been collected and stocked for this purpose [21] [22] [23] . Homologous class I HLA-type products need to be compatible with only one of the two class I HLA loci of the recipient and thus can be used for several orders more patients than heterologous products. It has been estimated that the collection of the 100 most frequent HLA-type lines will satisfy about 80% of the Japanese population [86] . Using this strategy, patients in need of HLA-compatible platelets can rely on a stocked platelet source that has already been assured for safety, rather than seeking compatible blood donors with uncertain availability. However, considering the highly variable HLA types that humans possess, the higher the coverage of the library, the exponentially larger the product line-up.
Finally, as a future strategy to minimize the risk of PTR, based on the feasibility of manipulating hiPSCs, class I HLA-nullified hiPSCs-derived platelets have been proposed. Using technologies such as shRNA, TALEN, or CRISPR/Cas9, HLA class I downregulation can be achieved via silencing or deletion of b2 microglobulin (b2M), which is an HLA class I-associated molecule (Fig. 4) [17, 87] . One concern, however, is that natural killer (NK) cells are known to attack HLA-downregulated cells [88] . Although the alloreactivity of NK cells has not been demonstrated against platelets, it may surface upon the transfusion of platelets with complete HLA deletion. In this regard, knockdown by shRNA might leave a minimal but sufficient level of class I HLA to prevent the activation of NK cells [89, 90] . The forced expression of recombinant non-polymorphic HLA-E or HLA-G fused to b2M for the purpose of suppressing NK cell activation via the NK receptor, CD94, has also been studied [49, 91, 92] .
As for PTR from HPA incompatibility, the frequency is lower than PTR by allo-HLA, but patients with anti-HPA antibodies could also manifest more critical clinical responses such as post-transfusion purpura (PTP) or fetal/neonatal alloimmune thrombocytopenia (FNAIT) [93] . In PTP, a few weeks after the transfusion of incompatible HPA platelets results in a platelet count that is somehow less than before the transfusion, suggesting the clearance of the patient's own platelets [93] . FNAIT occurs during pregnancy, in which the mother's immune system reacts to HPA-incompatible fetal platelets. The produced maternal anti-allo-HPA antibody transitions through the placenta to cause thrombocytopenia in the newborn, which risks severe complications and long-term disabilities [93, 94] . The antigenicity of allo-HPA stems mostly from single nucleotide polymorphisms (SNPs) in HPA molecules [93] [94] [95] . Because most HPA expression is indispensable, the elimination strategy proposed for HLA cannot be applied, but CRISPR/Cas9 technology can be used to convert SNPs and change the HPA allotype [25] .
Taken together, technologies that can manipulate platelet antigens are expected to provide alloantigen-matching platelets. A single qualified HLA-null MK line can serve as a universal HLA-type master cell for mass production and also as basic material for further modification of HPA-matching platelets (Fig. 4) .
Conclusion
The ex vivo production of platelets has significantly progressed over recent years. The generation of expandable MK lines coupled with the development of bioreactors and the discovery of effective agents have markedly improved the efficiency and yield, moving this field toward clinical application. Owing to the natural safety of platelets as anucleate, non-proliferating cells, clinical trials are expected in the foreseeable future. In this regard, ex vivo platelets are expected to lead the field of iPSC-based regenerative medicine owing to the huge number of patients requiring platelet transfusion.
There are still hurdles to be overcome, however, including production of platelets at high yield in GMP conditions, production of platelets with function that compares with fresh blood-derived platelets, and purification to Fig. 4 . Rationalization of iPSC-derived platelets by HLA nullification and HPA conversion. By knocking down or knocking out b2-microglobulin (b2 m), HLA on platelets can be nullified to evade alloimmunity mediated by anti-HLA antibodies. HLA-null imMKCL leads to the economical production of uniformly highquality platelets. Further manipulation of HPA genes could be applied to evade HPA-related alloimmunity.
eliminate unwanted cells and substances, along with methods that confirm safety and provide optimal preservation [49] . Nevertheless, considering the large number of researchers and nations working in this field, it is expected that within a few years, the first clinical trials could be attempted, and quite possibly in multiple countries. This technology is expected to provide a safe and affordable clinical measure that circumvents any shortages or defects in the donor-derived platelet supply.
